Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
【译】阿达木单抗治疗是降低溃疡性结肠炎患者的住院风险。
2
For adalimumab, etanercept and rituximab, an increase of at least 40% was seen in the number of people experiencing improved symptoms, when the drugs were compared to placebos.